Gwaltney Jack M, Winther Birgit, Patrie James T, Hendley J Owen
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
J Infect Dis. 2002 Jul 15;186(2):147-54. doi: 10.1086/341455. Epub 2002 Jul 3.
A randomized, controlled, double-masked clinical trial was conducted with a combination antiviral-antimediator treatment for experimental rhinovirus colds. In all, 150 healthy men and women (aged 18-51 years) were randomly assigned to 1 of 3 groups: intranasal interferon (IFN)-alpha2b (6 x 10(6) U every 12 h x 3) plus oral chlorpheniramine (12 mg extended release) and ibuprofen (400 mg) every 12 h for 4.5 days (n=59 subjects); intranasal placebo plus oral chlorpheniramine and ibuprofen (n=61 subjects); or intranasal and oral placebos (n=30 subjects). Treatment was started 24 h after intranasal viral challenge. During the 4.5 days of treatment with IFN-alpha2b, chlorpheniramine, and ibuprofen, the daily mean total symptom score was reduced by 33%-73%, compared with placebo. Treatment reduced the severity of rhinorrhea, sneezing, nasal obstruction, sore throat, cough, and headache and reduced nasal mucus production, nasal tissue use, and virus concentrations in nasal secretions. IFN-alpha2b added to the effectiveness of chlorpheniramine and ibuprofen and was well tolerated.
开展了一项随机、对照、双盲临床试验，采用抗病毒-抗介质联合疗法治疗实验性鼻病毒感冒。总共150名健康男性和女性（年龄18 - 51岁）被随机分为3组中的1组：鼻内给予α-2b干扰素（每12小时6×10⁶单位，共3次）加口服氯苯那敏（缓释片12毫克）和布洛芬（400毫克），每12小时一次，共4.5天（n = 59名受试者）；鼻内给予安慰剂加口服氯苯那敏和布洛芬（n = 61名受试者）；或鼻内和口服均给予安慰剂（n = 30名受试者）。在鼻内病毒攻击后24小时开始治疗。在用α-2b干扰素、氯苯那敏和布洛芬治疗的4.5天期间，与安慰剂相比，每日平均总症状评分降低了33% - 73%。治疗减轻了鼻漏、打喷嚏、鼻塞、咽痛、咳嗽和头痛的严重程度，并减少了鼻黏液分泌、鼻组织使用以及鼻分泌物中的病毒浓度。α-2b干扰素增强了氯苯那敏和布洛芬的疗效，且耐受性良好。
